Ascelia Pharma Meets Primary Endpoint in Phase 3 Study of Orviglance Liver Imaging Contrast Agent Drug Candidate
May 8, 2024 — Swedish biotech company Ascelia Pharma AB has announced that its liver imaging drug candidate, Orviglance, significantly improved visualization of focal liver lesions, successfully meeting the primary endpoint in the pivotal Phase 3 study …